Axcynsis Therapeutics Advances Cancer Treatment with FDA IND Clearance for AT03-65#Singapore#Axcynsis#CLDN6#AT03-65
Axcynsis Therapeutics Advances Cancer Treatment with FDA IND Clearance for AT03-65
Axcynsis Therapeutics has received FDA clearance for AT03-65, an ADC targeting CLDN6-positive tumors, enabling a new clinical trial. This marks a significant innovation in cancer therapy.
third-news.com
January 15, 2025 at 2:35 PM
Axcynsis Therapeutics Advances Cancer Treatment with FDA IND Clearance for AT03-65#Singapore#Axcynsis#CLDN6#AT03-65